Merck & Co. vs Regeneron Pharmaceuticals

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (77 vs 79)
Merck & Co. logo

Merck & Co.

LeaderHealthcare Tech

Enterprise

Global pharma anchored by Keytruda ($25B cancer drug); $63.6B FY2024 revenue; Gardasil China collapse 2024 ($2B loss); Winrevair PAH approval 2024; Keytruda patent cliff 2028-2030 is defining challenge.

AI VisibilityBeta
Overall Score
B77
Category Rank
#45 of 596
AI Consensus
88%
Trend
stable
Per Platform
ChatGPT
79
Perplexity
74
Gemini
76

About

Merck & Co. is one of the world's largest research-driven pharmaceutical companies, founded in the United States in 1891 as a subsidiary of the German Merck KGaA and now an independent American company headquartered in Rahway, New Jersey, trading on NYSE (MRK). The company generated approximately $63.6 billion in revenues for FY2024 under CEO Robert Davis, anchored by Keytruda (pembrolizumab)—the world's best-selling cancer drug—which generated approximately $25 billion in global sales as the dominant checkpoint inhibitor immunotherapy across over 40 approved tumor indications including lung cancer, melanoma, bladder cancer, cervical cancer, and dozens more. Merck's animal health subsidiary, Merck Animal Health, is a global leader in livestock and companion animal medicines including Bravecto (flea/tick prevention) and contributes approximately $6 billion in revenues.

Full profile
Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals

LeaderHealthcare Tech

Enterprise

Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.

AI VisibilityBeta
Overall Score
B79
Category Rank
#30 of 596
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
77
Perplexity
76
Gemini
75

About

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.

Full profile

AI Visibility Head-to-Head

77
Overall Score
79
#45
Category Rank
#30
88
AI Consensus
73
stable
Trend
stable
79
ChatGPT
77
74
Perplexity
76
76
Gemini
75
78
Claude
85
76
Grok
74

Key Details

Category
Enterprise
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.